Praxis Precision Medicines, Inc. (PRAX)
$1.05
Rating:
Recommendation:
-
| Symbol | PRAX |
|---|---|
| Price | $1.05 |
| Beta | 3.027 |
| Volume Avg. | 0.91M |
| Market Cap | 68.434M |
| Shares () | - |
| 52 Week Range | 0.79-5.25 |
| 1y Target Est | - |
| DCF Unlevered | PRAX DCF -> | |
|---|---|---|
| DCF Levered | PRAX LDCF -> | |
| ROE | -167.48% | Strong Sell |
| ROA | -185.91% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 51.27% | Buy |
| P/E | -0.30 | Neutral |
| P/B | 0.64 | Buy |
Latest PRAX news
About
Download (Excel)Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.